AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21988668
Drug: 6-week titration
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-week titration (biweekly quarter-dose increments over 6 weeks to full dose)
Trial: 21988668
Drug: No titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No titration (full dose over 8 weeks)
Trial: 16532500
Drug: Decitabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (15 mg/m2 intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks)
Trial: 12684288
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled fluticasone (880 micro g/d) for 28 days
Trial: 9689201
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens 0.625 mg/day for 21 days plus chlormadinone 2 mg for the last 12 days (Group I)
Trial: 9689201
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens 0.625 mg/day plus chlormadinone 1 mg/day, continuous and uninterrupted (Group II)
Trial: 8126242
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser followed by air‐powder abrasive treatment
Trial: 2671559
Drug: Daily rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rifampicin (600 mg), ethionamide (500 mg), and dapsone (100 mg) or clofazimine (100 mg) for 8 weeks followed by once weekly rifampicin (600 mg) and daily ethionamide (500 mg) and dapsone (100 mg) or clofazimine (100 mg) for 44 weeks
Trial: 791442
Drug: Streptokinase (2,500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (2,500,000 IU intravenous infusion over 24 hours)
Trial: 31665326
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment at 67 µg/kg/day for 1 year
Trial: 25398590
Drug: Fibrin-sealant-delivered cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fibrin-sealant-delivered cisplatin chemotherapy (FS)
Trial: 25398590
Drug: Cisplatin hyperthermic
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin hyperthermic intraperitoneal perfusion chemotherapy (CHIC)
Trial: 21146267
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (3 educational seminars, assistance with action plans, monthly monitoring)
Trial: 17050042
Drug: High-titer varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titer varicella vaccine (PUVV) - approximately 50,000 PFU
Trial: 17050042
Drug: Lower-titer formulation
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-titer formulation of VARIVAX - approximately 5400 PFU
Trial: 17050042
Drug: High-titer varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titer varicella vaccine (PUVV)
Trial: 12624290
Drug: Lower concentrations
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower concentrations of IL-10 (<6 pg/mL)
Trial: 11008922
Drug: 25,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25,000 IU of retinol daily
Trial: 9081107
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (11.4 gm)
Trial: 9081107
Drug: Insulin solution
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin solution (225 IU insulin, glucose with glucose clamp technique, and potassium) in addition to amino acid infusion
Trial: 8382132
Drug: Dihydralazine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (7.5 mg)
Trial: 8382132
Drug: Enalaprilat (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (1.25 mg)
Trial: 31384411
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil supplementation (5 g of flaxseed oil containing 2.5 g α‐Linolenic acid)
Trial: 31384411
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 ml of 1.5% fat milk)
Trial: 30258212
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus zoledronic acid
Trial: 22471362
Drug: Keishi-bukuryo-gan (3.75g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keishi-bukuryo-gan (3.75g twice daily for seven days)
Trial: 20860913
Drug: Golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 100 mg every 4 weeks
Trial: 18569471
Drug: Intravaginal Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal Misoprostol 25 microm 4‐hourly
Trial: 18569471
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone 0.5 mg 12 hourly
Trial: 15799717
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (80 mg of caffeine)
Trial: 15799717
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (< 2 mg of caffeine)
Trial: 12447087
Drug: Force-feedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Force-feedback treatment for lower paretic limb
Trial: 12447087
Drug: Force-feedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Force-feedback treatment for upper paretic limb
Trial: 6617596
Drug: Polytherapy (reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytherapy (reduction of anticonvulsants)
Trial: 6617596
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum levels of anticonvulsants
Trial: 6617596
Drug: Monotherapy (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (high serum levels)
Trial: 29939243
Drug: 2-visit intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-visit intradermal vaccination (2 doses of 0.1 mL ID of HDCV at days 0 and 7)
Trial: 29939243
Drug: 3-visit standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-visit standard vaccination (single dose of 0.1 mL ID at days 0, 7, and 28)
Trial: 25428755
Drug: Ropivacaine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (7.5 mg/mL)
Trial: 25428755
Drug: NaCl (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (9 mg/mL)
Trial: 17309378
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (20 minutes of massage on five occasions)
Trial: 11386490
Drug: d-amphetamine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (10-20 mg)
Trial: 11386490
Drug: methylphenidate (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate (20-40 mg)
Trial: 8187012
Drug: New pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pharmaceutical agents
Trial: 3046283
Drug: APSAC (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APSAC (30 U as intravenous injection)
Trial: 3046283
Drug: APSAC and
RxNorm normalized name: APSAC
DrugBank: Anistreplase (DB00029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APSAC and Heparin
Trial: 30721549
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (GH)
Trial: 22999815
Drug: Printed literature
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Printed literature about alcohol and drug use risks (Control)
Trial: 21701341
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound treatment at 59 J/cm
Trial: 21701341
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound treatment at 47 J/cm
Trial: 20175279
Drug: norbactin (norfloxacin)
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norbactin (norfloxacin) 400 mg twice a day for 7 days
Trial: 20175279
Drug: furamag 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furamag 50 mg 3 times a day for 10 days
Trial: 16944396
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisolone (Pred)
Trial: 16944396
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisolone plus 4 mg salbutamol (Pred-Sal)
Trial: 2966140
Drug: Teicoplanin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (400 mg on induction of anaesthesia and 200 mg 24 h later)
Trial: 2966140
Drug: Teicoplanin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (three doses of 400 mg)
Trial: 2966140
Drug: Tobramycin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (80 mg tds for three days) and flucloxacillin (500 mg qds for 5 days)
Trial: 30254744
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of medicine pill boards
Trial: 27107960
Drug: Naprapathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprapathic manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Trial: 27107960
Drug: Naprapathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprapathic manual therapy excluding spinal manipulation
Trial: 27107960
Drug: Naprapathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprapathic manual therapy excluding stretching
Trial: 27107960
Drug: Naprapathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprapathic manual therapy (all groups)
Trial: 19218249
Drug: Nadolol +
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol + Isosorbide-5-mononitrate alone (Drug)
Trial: 19218249
Drug: Nadolol +
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol + Isosorbide-5-mononitrate combined with EBL (Drug + EBL)
Trial: 17204097
Drug: Serial glycolic
RxNorm normalized name: glycolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial glycolic acid peels, topical azelaic acid 20% cream (b.i.d.), and adapalene 0.1% gel (q.i.d.)
Trial: 17204097
Drug: Topical azelaic
RxNorm normalized name: azelaic acid Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical azelaic acid and adapalene (control group)
Trial: 12504397
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m(2) intravenously every 3 months for 24 months
Trial: 12419743
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m(2)
Trial: 10422931
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg neostigmine in the axillary plexus and saline solution subcutaneously (group 2)
Trial: 10422931
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution in the axillary plexus and 500 microg neostigmine subcutaneously (group 3)
Trial: 10422931
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution in the axillary plexus and subcutaneously (group 1)
Trial: 401005
Drug: Papaverine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (150 mg BID for 1 week, then 300 mg BID for 5 weeks)
Trial: 401005
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (6-week no drug control condition)
Trial: 28413925
Drug: Triple-bead mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-bead mixed amphetamine salts (MAS) 25, 50, or 75 mg
Trial: 28101779
Drug: Topical EMLA
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical EMLA with breastfeeding (EB group)
Trial: 28101779
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant spray with breastfeeding (VB group)
Trial: 25136638
Drug: Omega-3 tablets
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 tablets (2.4 gr/day)
Trial: 25136638
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E tablets (400 IU/day)
Trial: 15338687
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol therapy (Group III)
Trial: 15338687
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol therapy (Group II)
Trial: 15338687
Drug: No calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcitriol therapy (Group I)
Trial: 11229829
Drug: Garlic oil
RxNorm normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic oil (GO) capsules, 12.3 mg/day for 16 weeks
Trial: 7735929
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 3 weeks
Trial: 7735929
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 2 weeks
Trial: 7735929
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with clarithromycin + sofalcone
Trial: 1976379
Drug: Terfenadine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 40 mg
Trial: 1976379
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terfenadine 40 mg and pseudoephedrine 60 mg
Trial: 380580
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of Bay g 5653
Trial: 380580
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of Bay g 5653
Trial: 380580
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of Bay g 5653
Trial: 26096765
Drug: AZD6482 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6482 + aspirin
Trial: 26096765
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (P2Y12 + PI3Kβ + COX‐1)
Trial: 20598967
Drug: Clopidogrel +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel + aspirin
Trial: 23497759
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating film (ODF) formulation of sildenafil, 50 mg (part 1)
Trial: 23497759
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet (FCT) formulation of sildenafil, 50 mg (part 1)
Trial: 23497759
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating film (ODF) formulation of sildenafil, 100 mg (part 2)
Trial: 23497759
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet (FCT) formulation of sildenafil, 100 mg (part 2)
Trial: 23497759
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events (AEs) with ODF and FCT formulations
Trial: 18090169
Drug: N-acetylcysteine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200 mg every 12 hrs, starting immediately before cardiac surgery)
Trial: 15200747
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CT) with nateglinide (120 mg, ac) and metformin (500 mg, tid)
Trial: 11115582
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with TAI of 120 mg/body cisplatin twice a month at 4-week intervals
Trial: 11115582
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with 200 mg/day oral 5‐FU or UFT every day
Trial: 9600369
Drug: Tamoxifen, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen, 40 mg/day
Trial: 7993983
Drug: Benazepril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (20 mg)
Trial: 7993983
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of aspirin and benazepril
Trial: 31669225
Drug: Preventive inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive inhalation of hypertonic saline
Trial: 19725815
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium ophthalmic solution (BF)
Trial: 19725815
Drug: Steroidal solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroidal solution (ST)
Trial: 17428949
Drug: Monovalent HPV16
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent HPV16 vaccine
Trial: 15797982
Drug: Proparacaine HCl
RxNorm normalized name: proparacaine HCl
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proparacaine HCl ophthalmic solution 0.5%
Trial: 9583551
Drug: Etomidate, 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate, 0.3 mg/kg, and fentanyl, 1 microg/kg
Trial: 9583551
Drug: Ketamine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine, 1 mg/kg, and fentanyl, 1 microg/kg
Trial: 8580227
Drug: CI-988 capsules/CCK-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-988 capsules/CCK-4
Trial: 8580227
Drug: Placebo capsules/CCK-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules/CCK-4
Trial: 8580227
Drug: Placebo capsules/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules/placebo
Trial: 2679240
Drug: L-carnitine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine, 3 g IV as a bolus, followed by continuous intravenous infusion of 2 mg/kg/min for thirty minutes
Trial: 27865117
Drug: Intraaortic balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraaortic balloon pump therapy
Trial: 25859764
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT-SAD) for 6 weeks, 12 sessions in a group format, 90 minutes each, administered by Ph.D. psychologists
Trial: 25859764
Drug: Light Therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light Therapy for 6 weeks, 10,000-lux cool-white fluorescent light, initiated at 30 minutes each morning
Trial: 18947437
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (0-2 g/d) for up to 10 weeks
Trial: 17725415
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) once daily (QD)
Trial: 17725415
Drug: Stavudine (d4T)
RxNorm normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine (d4T) twice daily
Trial: 11728950
Drug: Prednisolone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.8 mg/kg/d) for 1 month
Trial: 8435260
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg‐1 and alfentanil 10 micrograms kg‐1
Trial: 8435260
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg‐1, alfentanil 10 micrograms kg‐1, and lignocaine 1 mg kg‐1
Trial: 8435260
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Trial: 8435260
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg‐1, alfentanil 20 micrograms kg‐1, and lignocaine 1 mg kg‐1